Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (9393)	4/10/2006 3:02:36 PM
From: Iamarangerboy	Respond to of 10280

so why would this be a positive for NBIX and not SEPR....http://www.forbes.com/2006/04/10/neurocrine-biosciences-pfizer-0410markets10.html?partner=yahootix Ambien Patent Extension Seen Positive For Pfizer, Neurocrine Peter Kang, 04.10.06, 1:11 PM ET Piper Jaffray reiterated an "outperform" rating on Neurocrine Biosciences ahead of the specialty drug firm's first-quarter earnings report. Analyst Thomas Wei wrote in a client note Monday that he remains confident that Neurocrine's insomnia drug indiplon will be approved by federal health regulators by the May 15 deadline, following meetings with Neurocrine senior management in March. The research analyst expects the company to launch the drug late with partner Pfizer (nyse: PFE - news - people ) in the second quarter or beginning of the third quarter with a "strong marketing effort." "We believe that Pfizer will put substantial resources behind the indiplon launch and are committed to more details than either Sepracor's Lunesta or Sanofi's Ambien," the analyst said. "We infer that this would also imply Pfizer will have a sales force competitive to, or greater than, Sepracor and Sanofi's sales forces, which could likely number greater than 2,000 [sales] reps in total." Wei noted that Sanofi-Aventis' request for six more months of exclusivity for Ambien bodes well for Pfizer and Neurocrine, since it would delay the generic launch of the first non-benzodiazapene sleeping pill and "would provide Neurocrine with several quarters to build the indiplon brand before the introduction of the first generic." The analyst maintained a $72 price target on Neurocine, saying the stock doesn't properly reflect the long-term potential of the indiplon royalty stream and the company's pipeline. Neurocrine is set to report first-quarter earnings on April 24.